The market for delta-like ligand 3 (DLL3) targeted therapies is rapidly expanding due to the rising prevalence of small cell lung cancer (SCLC) and neuroendocrine tumors. Advancements in antibody-drug conjugate (ADC) technology and increased clinical trial activity are driving the development of DLL3-targeted therapies. Strategic collaborations and growing interest from biopharma companies are accelerating market […]
Tag: biomarker
The Future of Blood-Based Metabolomics in Healthcare
In the evolving landscape of biotechnology, the role of blood-based metabolomics is becoming increasingly pivotal, acting as a dynamic catalyst in multiple areas of biomedical research. As a cornerstone in biomarker discovery, disease comprehension, and personalized medicine, the impact of this discipline is transformative, with the potential to revolutionize healthcare outcomes and treatments. As the […]
Strategic Partnership to Enhance Drug Development
In a significant leap forward for the pharmaceutical industry, Radyus Research and Eurofins CDMO Alphora have announced a strategic alliance geared towards accelerating drug development and streamlining the path from lab to market. As the boundaries of biotechnology continue to expand, this collaboration signifies a burgeoning trend in the industry: the drive for integrated, end-to-end […]
Taurine as Aging Biomarker: NIH Findings
In a groundbreaking study, scientists at the National Institutes of Health (NIH) have challenged the conventional belief that declining taurine levels universally signify aging. The researchers found that circulating taurine, a conditionally essential amino acid crucial for several biological functions, is not a reliable biomarker for aging. Their findings, published in Science, underscore the need […]
C5aR1 as Biomarker for Cutaneous Squamous Cell Carcinoma
The burgeoning field of immuno-oncology has been revolutionized by the promise of targeting the C5a-C5aR1 axis for advanced cutaneous squamous cell carcinoma (cSCC), according to a recent report published in the American Journal of Pathology. The study’s findings have electrified the biotech landscape, suggesting a novel therapeutic approach that could significantly alter the course of […]
AI Enhances Cancer Diagnosis Speed
Utilizing digital tissue slides from over 1,400 cancer patients, researchers developed DeepHRD, an AI platform trained to predict HRD positivity in breast and ovarian cancers. DeepHRD’s multiresolution decision process mimics pathologists’ protocols, detecting subtle tissue structure changes indicative of HRD status. Unlike visual tests, DeepHRD accurately identifies the HRD biomarker, offering a faster and potentially […]
Enhancing Bioanalysis Through Extreme Robustness
Alderley Analytical is revolutionizing bioanalysis by providing high-quality, interruption-free results to customers, ensuring the safe and efficient development of new drugs. Sally Hannam, Scientific Director at Synexa Life Sciences, praises the Xevo TQ Absolute XR Mass Spectrometer, ACQUITY™ Premier UPLC™ System, and waters_connect™ Software for their unparalleled reproducibility and accuracy in analyzing crashed human plasma. […]
Revolutionizing Medicine with AI-Driven Biomarker Discovery
Predictive Oncology Inc. is at the forefront of revolutionizing medicine through AI-driven biomarker and drug discovery for precision health. With a vast biobank of diverse live-cell tumor specimens, the company is uniquely positioned to drive long-term value and shape the future of cancer treatment and drug development. Collaborating with UPMC Magee-Womens Hospital, Predictive Oncology developed […]
Revolutionizing Medicine with AI-Driven Biomarker Discovery
Predictive Oncology Inc. is at the forefront of revolutionizing medicine through AI-driven biomarker and drug discovery for precision health. With a vast biobank of diverse live-cell tumor specimens, the company is uniquely positioned to drive long-term value and shape the future of cancer treatment and drug development. Collaborating with UPMC Magee-Womens Hospital, Predictive Oncology developed […]
Autoimmunity and Pathogenesis: A Complex Interplay
The immune system’s protective role can backfire with autoimmunity, where it mistakenly attacks the body’s own cells. This phenomenon, known as autoimmunity, leads to a spectrum of diseases ranging from life-threatening organ failure to subtle shifts in biomarker expression without immediate symptoms. Understanding the interplay between autoimmunity and pathogenesis is crucial for developing effective treatments […]
Ultrasensitive DNA Biosensor for Fusobacterium Detection
Fusobacterium nucleatum, a bacterium associated with colorectal cancer, contains the fadA gene, a valuable early diagnostic biomarker. The study highlights the integration of CRISPR/Cas12a system and an improved electrochemiluminescence (ECL) biosensor for ultrasensitive detection. CRISPR/Cas-based sensors face challenges like probe entanglement and reduced enzyme efficiency, but ECL offers superior spatiotemporal control and background noise reduction, […]
University of Houston Secures Funding for Cancer Biomarker Facility Launch
In a groundbreaking development, the University of Houston has secured $3M to establish a state-of-the-art Cancer Immunotherapy Biomarker Core facility. This cutting-edge facility is set to revolutionize biomarker discovery, enhance immunotherapy targeting, and bolster research capabilities throughout Texas. By boosting the state’s standing in cancer research, this initiative promises to drive advancements in patient outcomes […]
